Moderna’s Phase 3 Data Raises the Bar for Cancer Vaccines
Moderna’s first Phase 3 trial data for an mRNA-based cancer vaccine, released in late 2025, has sparked debate over whether the treatment is truly needed in a crowded oncology market. The result marks a milestone for the mRNA platform beyond COVID-19, but analysts caution that the initial data only answers part of the question.
The vaccine, developed in partnership with Merck, targets high-risk melanoma patients. While the trial met its primary endpoint, the key uncertainty is whether the vaccine can deliver durable relapse-free survival over years, not just months.
Why Beating Keytruda Is Not the Main Event
Merck’s Keytruda (pembrolizumab) already dominates first-line melanoma treatment, with 2025 global sales estimated at over $25 billion. Moderna’s vaccine is not designed to replace Keytruda but to complement it, potentially reducing the risk of cancer returning after surgery.
The real test, according to oncologists, is long-term follow-up data. Early Phase 2 results showed a 44% reduction in the risk of recurrence or death versus Keytruda alone at 18 months. Phase 3 data must confirm that benefit holds at three and five years, a standard the FDA now expects for adjuvant therapies.
The Relapse-Free Survival Threshold That Matters
Investors should focus on the hazard ratio for relapse-free survival (RFS) in the final analysis. A ratio below 0.75 would likely be considered clinically meaningful. The Phase 2 trial reported a hazard ratio of 0.56, but that was a small study.
Moderna has guided that full Phase 3 results, including RFS at 36 months, will be presented at a major medical conference in 2027. Until then, the stock will trade on sentiment rather than hard data.
Manufacturing Scale and Cost Concerns
Moderna’s individualized neoantigen therapy requires sequencing each patient’s tumor and manufacturing a custom mRNA vaccine within weeks. The company has invested in a dedicated facility in Massachusetts, but scaling to thousands of patients per year remains unproven.
Analysts estimate the cost per patient could exceed $100,000, raising questions about reimbursement. Merck’s involvement provides commercial infrastructure, but pricing negotiations with payers will be critical.
Competitive Landscape Beyond Keytruda
BioNTech and Roche are also developing mRNA cancer vaccines, with Phase 2 data expected in 2027. Meanwhile, checkpoint inhibitors like Opdivo and Yervoy remain standard options. Moderna’s first-mover advantage in Phase 3 could be fleeting if competitors show better durability.
Shares of Moderna have fallen 60% from their 2021 peak, reflecting declining COVID revenue. A successful cancer vaccine could re-rate the stock, but only if long-term data supports a durable benefit.
What to Watch: 36-Month RFS Data in 2027
The next major catalyst is the 36-month relapse-free survival analysis from the Phase 3 trial, expected in the second half of 2027. If the hazard ratio remains below 0.75 with manageable side effects, Moderna could file for approval. A ratio above 0.85 would likely derail the program.
Merck’s stock, meanwhile, may react to any perceived threat to Keytruda’s franchise. For now, the two companies remain partners, but the market will soon need clarity on whether the vaccine is a complement or a competitor.
Sources: marketwatch.com · CNBC · AP News · Yahoo Finance · Reuters